Chagas disease is caused by the parasite Trypanosoma cruzi, which is transmitted to animals and people by insect vectors that are found only in the Americas. Chagas disease and Leishmaniasis are life-threatening illnesses caused by the protozoan parasites Leishmania spp. and Trypanosoma cruzi, respectively. They are known as “neglected diseases” due to the lack of effective drug treatments and the scarcity of research work devoted to them. Therefore, the development of novel and effective drugs is an important and urgent need. Natural products are an important source of bioactive molecules for the development of new drugs. Recently, studies showed an interesting cytotoxic action of Stilbene ST18 and the Terphenyl TR4 compounds in Leishmania.
In this study, we evaluated the in vitro trypanocidal activity of ST18 and TR4 and Nifurtimox, drug used for the treatment of Chagas disease. In addition, we evaluated the compounds action in infected macrophages with Trypanosoma cruzi. Results showed that three compounds exhibited significant activity against Trypanosoma compared to Nifurtimox. ST18 and TR4 compounds inhibited Trypanosoma growth with IC50 values of 4.5 and 32 μM, respectively. The treatment of infected macrophages with trypanosomes with the IC90 compounds showed a reduction of infection compared to control: ST18 reduced the infected cells to 52 %, TR4 reduced the infected cells to 63%. In conclusion, these news compounds could be considered as promising lead drugs for the development of new therapies for the treatment of Chagas disease
